Abstract

BACKGROUND A common adverse effect of 5-fluorouracil (5-FU) in chemotherapy is intestinal mucositis (IM), which significantly impacts patients' quality of life. To date, no effective long-term treatment is available for IM. Dihydrocaffeic acid (DHCA), a bioactive dietary compound from Gynura bicolor, exhibits potent anti-inflammatory and antioxidant properties. However, the exact mechanisms through which DHCA mediates its preventive and therapeutic effects on 5-FU-induced IM remain unclear. PURPOSE This study aims to evaluate the protective and therapeutic potential of DHCA against 5-FU-induced intestinal mucositis and to elucidate the underlying molecular mechanisms. METHODS An intestinal mucositis model was successfully established using 5-FU to explore the effects of DHCA. Subsequently, multi-omics and network pharmacology analyses were performed to elucidate the pathways potentially implicated in the effects of DHCA. Validation experiments were conducted in both mouse and cell models. RESULTS In vivo experiments demonstrated that prophylactic administration of DHCA markedly attenuated multiple 5-FU-induced adverse effects, including body weight loss, elevated colonic inflammation scores, excessive production of pro-inflammatory cytokines, goblet cell depletion, colon shortening, and disruption of tight junction integrity. Integrated multi-omics and network pharmacology analyses further suggested that the protective effects of DHCA are closely associated with the regulation of inflammation- and lipid metabolism-related signaling pathways. Molecular docking and results from multiple experiments revealed a direct interaction between DHCA and p38 MAPK, supporting its role in suppressing inflammatory signaling.